Proteomic-coupled-network analysis of T877A-androgen receptor interactomes can predict clinical prostate cancer outcomes between white (non-hispanic) and African-American groups

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Zaman, Naif ^a   Giannopoulos, Paresa N ^b   Chowdhury, Shafinaz ^a,b   Bonneil, Eric ^c   Thibault, Pierre ^c   Wang, Edwin ^a   Trifiro, Mark ^b,d   Paliouras, Miltiadis ^b,d  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ANDROGEN RECEPTOR; ANDROSTANOLONE; CYPROTERONE ACETATE; DEXAMETHASONE; ESTRADIOL; METRIBOLONE; MIBOLERONE; PROGESTERONE; TESTOSTERONE; THREONINE; AR PROTEIN, HUMAN; SEX HORMONE;

AFFINITY CHROMATOGRAPHY; AFRICAN AMERICAN; ARTICLE; BINDING AFFINITY; CAUCASIAN; CONTROLLED STUDY; COPY NUMBER VARIATION; GENE EXPRESSION PROFILING; GENE REARRANGEMENT; GENETIC VARIABILITY; GLEASON SCORE; HUMAN; HUMAN CELL; LIGAND BINDING; MALE; MICROARRAY ANALYSIS; MOLECULAR DYNAMICS; PROSTATE CANCER; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEOMICS; RACE DIFFERENCE; RNA EXTRACTION; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TANDEM MASS SPECTROMETRY; TRANSACTIVATION; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; ETHNOLOGY; GENETICS; METABOLISM; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; PROTEIN SECONDARY STRUCTURE; SURVIVAL; TUMOR CELL LINE;

AFRICAN AMERICANS; BINDING SITES; CELL LINE, TUMOR; EUROPEAN CONTINENTAL ANCESTRY GROUP; GONADAL STEROID HORMONES; HUMANS; MALE; MODELS, MOLECULAR; PROGNOSIS; PROSTATIC NEOPLASMS; PROTEIN STRUCTURE, SECONDARY; PROTEOMICS; RECEPTORS, ANDROGEN; SURVIVAL ANALYSIS;

EID: 84912122995     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0113190     Document Type: Article

References (90)

1. Kumar A, White TA, MacKenzie AP, Clegg N, Lee C, et al. (2011) Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci U S A 108: 17087-17092.
2. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, et al. (2011) The genomic complexity of primary human prostate cancer. Nature 470: 214-220.
3. Barbieri CE, Tomlins SA (2014) The prostate cancer genome: Perspectives and potential. Urol Oncol 32: 15-22.
4. Xu X, Zhu K, Liu F, Wang Y, Shen J, et al. (2013) Identification of somatic mutations in human prostate cancer by RNA-Seq. Gene 519: 343-347.
5. Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, et al. (2013) Punctuated evolution of prostate cancer genomes. Cell 153: 666-677.
6. Wu C, Wyatt AW, Lapuk AV, McPherson A, McConeghy BJ, et al. (2012) Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer. J Pathol 227: 53-61.
7. Hieronymus H, Sawyers CL (2012) Traversing the genomic landscape of prostate cancer from diagnosis to death. Nat Genet 44: 613-614.
8. Bielas JH, Loeb KR, Rubin BP, True LD, Loeb LA (2006) Human cancers express a mutator phenotype. Proc Natl Acad Sci U S A 103: 18238-18242.
9. Venkatesan RN, Bielas JH, Loeb LA (2006) Generation of mutator mutants during carcinogenesis. DNA Repair (Amst) 5: 294-302.
10. Vogelstein B, Kinzler KW (2002) The genetic basis of human cancer. New York: McGraw-Hill, Medical Pub. Division. xv, 821 p.
11. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, et al. (1999) Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59: 2511-2515.
12. Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, et al. (2013) A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer discovery 3: 1020-1029.
13. Korpal M, Korn JM, Gao X, Rakiec DP, Ruddy DA, et al. (2013) An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer discovery 3: 1030-1043.
14. Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, et al. (1994) Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 54: 2861-2864.
15. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, et al. (1995) Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332: 1393-1398.
16. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, et al. (1990) A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to antiandrogens. Biochem Biophys Res Commun 173: 534-540.
17. Paliouras M, Zaman N, Lumbroso R, Kapogeorgakis L, Beitel LK, et al. (2011) Dynamic rewiring of the androgen receptor protein interaction network correlates with prostate cancer clinical outcomes. Integrative biology : quantitative biosciences from nano to macro 10: 1020-1032.
18. Beitel LK, Sabbaghian N, Alarifi A, Alvarado C, Pinsky L, et al. (1995) Characterization of normal and point-mutated human androgen receptors expressed in the baculovirus system. J Mol Endocrinol 15: 117-128.
19. Saba J, Bonneil E, Pomies C, Eng K, Thibault P (2009) Enhanced sensitivity in proteomics experiments using FAIMS coupled with a hybrid linear ion trap/Orbitrap mass spectrometer. J Proteome Res 8: 3355-3366.
20. Kearney P, Thibault P (2003) Bioinformatics meets proteomics-bridging the gap between mass spectrometry data analysis and cell biology. J Bioinform Comput Biol 1: 183-200.
21. Awan A, Bari H, Yan F, Moksong S, Yang S, et al. (2007) Regulatory network motifs and hotspots of cancer genes in a mammalian cellular signalling network. IET Syst Biol 1: 292-297.
22. Cui Q, Ma Y, Jaramillo M, Bari H, Awan A, et al. (2007) A map of human cancer signaling. Mol Syst Biol 3: 152.
23. Cui Q, Yu Z, Purisima EO, Wang E (2006) Principles of microRNA regulation of a human cellular signaling network. Mol Syst Biol 2: 46.
24. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, et al. (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18: 11-22.
25. Li J, Lenferink AE, Deng Y, Collins C, Cui Q, et al. (2010) Identification of highquality cancer prognostic markers and metastasis network modules. Nature communications 1: 34.
26. Ramaswamy S, Ross KN, Lander ES, Golub TR (2003) A molecular signature of metastasis in primary solid tumors. Nat Genet 33: 49-54.
27. Case DA, Cheatham TE 3rd, Darden T, Gohlke H, Luo R, et al. (2005) The AMBER biomolecular simulation programs. J Comput Chem 26: 1668-1688.
28. Gotz AW, Williamson MJ, Xu D, Poole D, Le Grand S, et al. (2012) Routine microsecond molecular dynamics simulations with AMBER on GPUs. 1. Generalized Born. Journal of Chemical Theory and Computation 8: 1542-1555.
29. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, et al. (2006) Comparison of multiple AMBER force fields and development of improved protein backbone parameters. Proteins 65: 712-725.
30. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML (1983) Comparison of simple potential functions for simulating liquid water. Journal of Chemical Physics 79: 926-935.
31. Darden T, York D, Pedersen L (1993) Particle mesh ewald-an N.Log(N) method for ewald sums in large systems. Journal of Chemical Physics 98: 10089-10092.
32. Ryckaert JP, Ciccotti G, Berendsen HJC (1977) Numerical-integration of cartesian equations of motion of a system with constraints-molecular-dynamics of N-alkanes. Journal of Computational Physics 23: 327-341.
33. Parker CE, Warren MR, Loiselle DR, Dicheva NN, Scarlett CO, et al. (2005) Identification of components of protein complexes. Methods Mol Biol 301: 117-151.
34. Bohl CE, Gao W, Miller DD, Bell CE, Dalton JT (2005) Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proceedings Of The National Academy Of Sciences Of The United States Of America 102: 6201-6206.
35. Zhao XY, Boyle B, Krishnan AV, Navone NM, Peehl DM, et al. (1999) Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a. J Urol 162: 2192-2199.
36. Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, et al. (2000) Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 6: 703-706.
37. Matias PM, Carrondo MA, Coelho R, Thomaz M, Zhao XY, et al. (2002) Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. J Med Chem 45: 1439-1446.
38. van de Wijngaart DJ, Molier M, Lusher SJ, Hersmus R, Jenster G, et al. (2010) Systematic structure-function analysis of androgen receptor Leu701 mutants explains the properties of the prostate cancer mutant L701H. J Biol Chem 285: 5097-5105.
39. Mahmoud AM, Zhu T, Parray A, Siddique HR, Yang W, et al. (2013) Differential effects of genistein on prostate cancer cells depend on mutational status of the androgen receptor. PLoS One 8: e78479.
40. Zhou J, Geng G, Shi Q, Sauriol F, Wu JH (2009) Design and synthesis of androgen receptor antagonists with bulky side chains for overcoming antiandrogen resistance. J Med Chem 52: 5546-5550.
41. Askew EB, Gampe RT Jr, Stanley TB, Faggart JL, Wilson EM (2007) Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone. J Biol Chem 282: 25801-25816.
42. Bohl CE, Wu Z, Miller DD, Bell CE, Dalton JT (2007) Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design. J Biol Chem 282: 13648-13655.
43. Zhao H, Kim Y, Wang P, Lapointe J, Tibshirani R, et al. (2005) Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines. Prostate 63: 187-197.
44. Wu AH, Gomez SL, Vigen C, Kwan ML, Keegan TH, et al. (2013) The California Breast Cancer Survivorship Consortium (CBCSC): prognostic factors associated with racial/ethnic differences in breast cancer survival. Cancer causes & control: CCC 24: 1821-1836.
45. Long J, Zhang B, Signorello LB, Cai Q, Deming-Halverson S, et al. (2013) Evaluating genome-wide association study-identified breast cancer risk variants in African-American women. PLoS One 8: e58350.
46. Lindner R, Sullivan C, Offor O, Lezon-Geyda K, Halligan K, et al. (2013) Molecular phenotypes in triple negative breast cancer from African American patients suggest targets for therapy. PLoS One 8: e71915.
47. Park HS, Bae JS, Noh SJ, Kim KM, Lee H, et al. (2013) Expression of DBC1 and androgen receptor predict poor prognosis in diffuse large B cell lymphoma. Translational oncology 6: 370-381.
48. Mikkonen L, Pihlajamaa P, Sahu B, Zhang FP, Janne OA (2010) Androgen receptor and androgen-dependent gene expression in lung. Mol Cell Endocrinol 317: 14-24.
49. Recchia AG, Musti AM, Lanzino M, Panno ML, Turano E, et al. (2009) A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells. Int J Biochem Cell Biol 41: 603-614.
50. Kaiser U, Hofmann J, Schilli M, Wegmann B, Klotz U, et al. (1996) Steroidhormone receptors in cell lines and tumor biopsies of human lung cancer. International journal of cancer Journal international du cancer 67: 357-364.
51. McGhan LJ, McCullough AE, Protheroe CA, Dueck AC, Lee JJ, et al. (2014) Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype. Annals of surgical oncology 21: 361-367.
52. Vera-Badillo FE, Templeton AJ, de Gouveia P, Diaz-Padilla I, Bedard PL, et al. (2014) Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. Journal of the National Cancer Institute 106: djt319.
53. Ren Q, Zhang L, Ruoff R, Ha S, Wang J, et al. (2013) Expression of androgen receptor and its phosphorylated forms in breast cancer progression. Cancer 119: 2532-2540.
54. Heemers HV, Tindall DJ (2007) Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 28: 778-808.
55. Ngan S, Stronach EA, Photiou A, Waxman J, Ali S, et al. (2009) Microarray coupled to quantitative RT-PCR analysis of androgen-regulated genes in human LNCaP prostate cancer cells. Oncogene 28: 2051-2063.
56. Lee W, Jiang Z, Liu J, Haverty PM, Guan Y, et al. (2010) The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 465: 473-477.
57. Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, et al. (2010) A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463: 191-196.
58. Marques RB, Dits NF, Erkens-Schulze S, van Weerden WM, Jenster G (2010) Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models. PLoS One 5: e13500.
59. Debes JD, Tindall DJ (2004) Mechanisms of androgen-refractory prostate cancer. N Engl J Med 351: 1488-1490.
60. Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1: 34-45.
61. Heinlein CA, Chang C (2004) Androgen receptor in prostate cancer. Endocr Rev 25: 276-308.
62. Ueda T, Mawji NR, Bruchovsky N, Sadar MD (2002) Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem 277: 38087-38094.
63. Baca SC, Garraway LA (2012) The genomic landscape of prostate cancer. Front Endocrinol (Lausanne) 3: 69.
64. Wang Q, Li W, Zhang Y, Yuan X, Xu K, et al. (2009) Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138: 245-256.
65. Loriot Y, Wyatt A, Al Nakouzi N, Beraldi E, Toren P, et al. (2013) Mechanisms of resistance to enzalutamide in LNCaP models. Cancer Res 73.
66. Massie CE, Adryan B, Barbosa-Morais NL, Lynch AG, Tran MG, et al. (2007) New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep 8: 871-878.
67. Chen H, Libertini SJ, George M, Dandekar S, Tepper CG, et al. (2010) Genome-wide analysis of androgen receptor binding and gene regulation in two CWR22-derived prostate cancer cell lines. Endocr Relat Cancer 17: 857-873.
68. Takayama K, Kaneshiro K, Tsutsumi S, Horie-Inoue K, Ikeda K, et al. (2007) Identification of novel androgen response genes in prostate cancer cells by coupling chromatin immunoprecipitation and genomic microarray analysis. Oncogene 26: 4453-4463.
69. Takayama K, Tsutsumi S, Katayama S, Okayama T, Horie-Inoue K, et al. (2011) Integration of cap analysis of gene expression and chromatin immunoprecipitation analysis on array reveals genome-wide androgen receptor signaling in prostate cancer cells. Oncogene 30: 619-630.
70. van Brabant AJ, Stan R, Ellis NA (2000) DNA helicases, genomic instability, and human genetic disease. Annu Rev Genomics Hum Genet 1: 409-459.
71. Chymkowitch P, Le May N, Charneau P, Compe E, Egly JM (2011) The phosphorylation of the androgen receptor by TFIIH directs the ubiquitin/proteasome process. The EMBO journal 30: 468-479.
72. Hubert L Jr, Lin Y, Dion V, Wilson JH (2011) Xpa deficiency reduces CAG trinucleotide repeat instability in neuronal tissues in a mouse model of SCA1. Hum Mol Genet 20: 4822-4830.
73. Lin Y, Wilson JH (2009) Diverse effects of individual mismatch repair components on transcription-induced CAG repeat instability in human cells. DNA repair 8: 878-885.
74. Mu XM, Chang CS (2003) TR2 orphan receptor functions as negative modulator for androgen receptor in prostate cancer cells PC-3. Prostate 57: 129-133.
75. Russo D, Durante C, Bulotta S, Puppin C, Puxeddu E, et al. (2013) Targeting histone deacetylase in thyroid cancer. Expert opinion on therapeutic targets 17: 179-193.
76. Palvimo JJ, Reinikainen P, Ikonen T, Kallio PJ, Moilanen A, et al. (1996) Mutual transcriptional interference between RelA and androgen receptor. Journal of Biological Chemistry 271: 24151-24156.
77. de Moissac D, Zheng H, Kirshenbaum LA (1999) Linkage of the BH4 domain of Bcl-2 and the nuclear factor kappaB signaling pathway for suppression of apoptosis. J Biol Chem 274: 29505-29509.
78. Abern MR, Bassett MR, Tsivian M, Banez LL, Polascik TJ, et al. (2013) Race is associated with discontinuation of active surveillance of low-risk prostate cancer: Results from the Duke Prostate Center. Prostate Cancer Prostatic Dis 16: 85-90.
79. Fukagai T, Namiki T, Carlile RG, Namiki M (2009) Racial differences in clinical outcome after prostate cancer treatment. Methods in molecular biology 472: 455-466.
80. Powell IJ (1998) Prostate cancer in the African American: is this a different disease? Seminars in urologic oncology 16: 221-226.
81. Chornokur G, Dalton K, Borysova ME, Kumar NB (2011) Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. The Prostate 71: 985-997.
82. Ellis SD, Blackard B, Carpenter WR, Mishel M, Chen RC, et al. (2013) Receipt of National Comprehensive Cancer Network guideline-concordant prostate cancer care among African American and Caucasian American men in North Carolina. Cancer 119: 2282-2290.
83. Kubricht WS 3rd, Williams BJ, Whatley T, Pinckard P, Eastham JA (1999) Serum testosterone levels in African-American and white men undergoing prostate biopsy. Urology 54: 1035-1038.
84. Marks LS, Hess DL, Dorey FJ, Macairan ML (2006) Prostatic tissue testosterone and dihydrotestosterone in African-American and white men. Urology 68: 337-341.
85. Gaston KE, Kim D, Singh S, Ford OH 3rd, Mohler JL (2003) Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. J Urol 170: 990-993.
86. Kim HS, Moreira DM, Jayachandran J, Gerber L, Banez LL, et al. (2011) Prostate biopsies from black men express higher levels of aggressive disease biomarkers than prostate biopsies from white men. Prostate Cancer Prostatic Dis 14: 262-265.
87. Lange EM, Sarma AV, Ray A, Wang Y, Ho LA, et al. (2008) The androgen receptor CAG and GGN repeat polymorphisms and prostate cancer susceptibility in African-American men: results from the Flint Men's Health Study. Journal of human genetics 53: 220-226.
88. Bratt O, Borg A, Kristoffersson U, Lundgren R, Zhang QX, et al. (1999) CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. British Journal of Cancer 81: 672-676.
89. Ding D, Xu L, Menon M, Reddy GP, Barrack ER (2004) Effect of a short CAG (glutamine) repeat on human androgen receptor function. The Prostate 58: 23-32.
90. Rodriguez-Gonzalez G, Cabrera S, Ramirez-Moreno R, Bilbao C, Diaz-Chico JC, et al. (2009) Short alleles of both GGN and CAG repeats at the exon-1 of the androgen receptor gene are associated to increased PSA staining and a higher Gleason score in human prostatic cancer. J Steroid Biochem Mol Biol 113: 85-91.